Deal Watch: Kite Inks Novel AML Target Discovery Tie-Up With HiFiBiO
Executive Summary
Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.
You may also be interested in...
Who Will Emerge As Best In Class Of The FGF21 Analogs In NASH?
Akero hopes to begin Phase III study of efruxifermin this year, with 89bio working to enter Phase III with pegozafermin in 2024. But just behind them, Boston Pharmaceuticals thinks it has a convenience and immunogenicity edge.
Akero’s Phase II Success Could Augur Brighter Days For NASH R&D
With Akero’s FGF21 analog showing ability to reduce fibrosis and resolve non-alcoholic steatohepatitis, some analysts think classmate BIO89-100 could yield a better overall profile. NASH data are starting to pour in.
Gilead Buys Pipeline-In-A-Product With $21bn Immunomedics Deal
The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.